The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Cancer and Cancer research. The concepts of her Internal medicine study are interwoven with issues in Gastroenterology and Surgery. Her Oncology research is multidisciplinary, incorporating elements of Biomarker, Carboplatin, Clinical trial and Biopsy.
Her Lung cancer research incorporates elements of Targeted therapy and Pharmacology. Her Cancer research includes elements of Blockade, Receptor tyrosine kinase and Drug resistance. Vassiliki A. Papadimitrakopoulou combines subjects such as Immune checkpoint, Cell, Epidermal growth factor receptor, Carcinogenesis and Immunology with her study of Cancer research.
Vassiliki A. Papadimitrakopoulou spends much of her time researching Internal medicine, Oncology, Lung cancer, Cancer research and Cancer. Her Chemotherapy, Phases of clinical research, Carboplatin and Radiation therapy study in the realm of Internal medicine interacts with subjects such as In patient. Her research in Oncology intersects with topics in Pembrolizumab and Clinical trial.
Her Lung cancer research is multidisciplinary, relying on both Targeted therapy and Immunotherapy. Her biological study spans a wide range of topics, including Mutant, Immune system, KRAS, Lung and Adenocarcinoma. Her Cancer study integrates concerns from other disciplines, such as Disease, Dysplasia, Pharmacology and Bioinformatics.
Her primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Phases of clinical research. Her Oncology study combines topics from a wide range of disciplines, such as Pembrolizumab, Nivolumab, Ipilimumab, Immunotherapy and Carboplatin. Her study looks at the intersection of Carboplatin and topics like Pemetrexed with Osimertinib and Hazard ratio.
Vassiliki A. Papadimitrakopoulou has included themes like Durvalumab, Cancer, Targeted therapy and Confidence interval in her Lung cancer study. The study incorporates disciplines such as Immune system and non-small cell lung cancer in addition to Cancer research. Her work in Phases of clinical research tackles topics such as Docetaxel which are related to areas like Locally advanced and Progression-free survival.
Internal medicine, Oncology, Lung cancer, Immunotherapy and Adverse effect are her primary areas of study. Internal medicine is represented through her Pembrolizumab, Carboplatin, Clinical endpoint, Pemetrexed and non-small cell lung cancer research. Her Oncology research includes elements of Regimen, Immune checkpoint inhibitors, Nivolumab, Ipilimumab and Radiation therapy.
Her Lung cancer research focuses on Targeted therapy and how it relates to Chemoimmunotherapy, Cancer research and Immune system. Her biological study deals with issues like Discontinuation, which deal with fields such as Intensive care medicine, Blockade, Drug development, Clinical study design and Erlotinib. While the research belongs to areas of Adverse effect, she spends her time largely on the problem of Rash, intersecting her research to questions surrounding Gefitinib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S. Mok;Yi Long Wu;Myung Ju Ahn;Marina C. Garassino.
The New England Journal of Medicine (2017)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou.
Lancet Oncology (2016)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann.
Cancer Discovery (2018)
Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
Lecia V. Sequist;Jean Charles Soria;Jonathan W. Goldman;Heather A. Wakelee.
The New England Journal of Medicine (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis;Lauren A. Byers;Lixia Diao;Vassiliki A. Papadimitrakopoulou.
Cancer Discovery (2015)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
Anne O'Donnell;Sandrine Faivre;Howard A. Burris;Daniel Rea.
Journal of Clinical Oncology (2008)
Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia
Joyce A. O’Shaughnessy;Gary J. Kelloff;Gary B. Gordon;Andrew J. Dannenberg.
Clinical Cancer Research (2002)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle;Lauren Averett Byers;Edward S. Kim;Pierre Saintigny.
Journal of the National Cancer Institute (2012)
Focus on head and neck cancer
Li Mao;Waun K Hong;Vassiliki A Papadimitrakopoulou.
Cancer Cell (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: